49 results on '"Mangia, Alessandra"'
Search Results
2. The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes
3. Sofosbuvir and Velpatasvir for Patients with HCV Infection
4. Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older
5. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
6. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
7. Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis
8. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis
9. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials
10. Interleukin-28B genetic variants in untreated Italian HCV-infected patients: a multicentre study
11. Long-term clinical outcomes and sustained virologic response (SVR) follow up of patients treated with sofosbuvir in the phase 3 studies: FISSION, POSITRON, FUSION, and NEUTRINO: P-413
12. A P70S Variant of the IFNλ4 Protein Displaying Decreased Activity is Associated with Improved Hepatitis C Virus Clearance and Reduced Hepatic Expression of Interferon-Stimulated Genes: 226
13. An Integrated Safety and Efficacy Analysis of >500 Patients with Compensated Cirrhosis Treated with Ledip-asvir/Sofosbuvir with or without Ribavirin: 82
14. Prognostic factors of hepatic decompensation and hepatocellular carcinoma in patients with transfusion-acquired HCV infection
15. In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions
16. Phyto-liposomes as nanoshuttles for water-insoluble silybin–phospholipid complex
17. Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
18. Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
19. Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution
20. Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
21. Genome-Wide Association Study of Spontaneous Resolution of Hepatitis C Virus Infection: Data From Multiple Cohorts
22. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials
23. Benefit of weight based dosages of Ribavirin (RBV) in combination with PegInterferon (PegIFN) α2a in naïve patients with HCV2 and HCV3: results of an Italian Randomized Controlled Trial, the WRITE study: 1737
24. Baseline predictors of null-response to peginterferon (PegIFN) α2a (40KD)/ribavirin (RBV) in treatment-naive patients with chronic hepatitis C (CHC) infected with HCV genotype 1: analysis of data from the multinational PROPHESYS cohorts: 811
25. Whatʼs new in HCV genotype 2 treatment
26. Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: Meta-analyses of randomized, controlled trials and implications for the future
27. Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring
28. High RAD51 mRNA expression characterize estrogen receptor-positive/progesteron receptor-negative breast cancer and is associated with patientʼs outcome
29. Inosine Triphosphatase Genetic Variants Are Protective Against Anemia During Antiviral Therapy for Hcv2/3 But Do Not Decrease Dose Reductions of Rbv Or Increase Svr
30. Individualizing treatment duration in hepatitis C virus genotype 2/3-infected patients
31. Hepatitis C pharmacogenetics: State of the art in 2010
32. Tailoring the length of antiviral treatment for hepatitis C
33. Management of patients with hepatitis C virus genotype 2 or 3: Comments on updated american association for the study of liver diseases practice guidelines#
34. Gene expression profile of Huh-7 cells expressing hepatitis C virus genotype 1b or 3a core proteins
35. Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection#
36. Reply
37. Lack of Correlation Between Serum Anti-HBcore Detectability and Hepatocellular Carcinoma in Patients With HCV-Related Cirrhosis
38. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial
39. Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV
40. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms
41. Sustained virological response to interferon-α is associated with improved outcome in HCV-related cirrhosis: A retrospective study
42. Short-Term Therapy for Patients with Hepatitis C Virus Genotype 2 or 3 Infection
43. Peginterferon Alfa-2b and Ribavirin for 12 versus 24 Weeks in HCV Infection
44. Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3
45. External Validation of Biochemical Indices for Noninvasive Evaluation of Liver Fibrosis in HCV Chronic Hepatitis
46. HLA class II favors clearance of HCV infection and progression of the chronic liver damage
47. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon α-2b for chronic hepatitis type C : Results of a multicenter randomized trial
48. HCV genotypes in patients with liver disease of different stages and severity
49. Pathogenesis of Chronic Liver Disease in Patients with Chronic Hepatitis B Virus Infection without Serum HBeAg
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.